EUVIMEDEUVIMED entdecken
Crossref

Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents

Sarah Tanveer, Wendy Camelo Castillo, Linda Wastila, Tarek A Hammad, Catherine E Cooke, John P A Ioannidis, Peter Doshi

Drug Safety · 2026-12 · 49 (12) · 1649-1656

DOI: 10.1007/s40264-026-01710-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, online erschienen am 30.10.2026. Verfasst von Sarah Tanveer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA. saraht24@stanford.edu. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Labeling, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The United States Prescribing Information (USPI), also known as the Food and Drug Administration (FDA) drug label, serves as a primary source of information for healthcare professionals to access reliable information on drug benefits and risks. Within the drug label, adverse events are listed across varying sections (e.g., Contraindications, Warnings and Precautions, Adverse Reactions). However, at present it is unclear what evidentiary thresholds FDA applies before including specific adverse event types in various sections of the drug label. To examine this question, we conducted an analysis of United States (US) regulations, guidance documents, standard operating procedures and policies published by FDA pertaining to the assessment of adverse events and drug labeling.

Objective

This study examines how causality assessments shape decisions regarding the inclusion and placement of adverse events in the US drug label.

Methods

We analyzed US regulations and policy documents published by FDA up to June 2024. Sources included the electronic Code of Federal Regulations, FDA policy documents (e.g., guidance documents, standard operating procedures, and policies) identified through searches of the FDA website and Westlaw legal database. Documents were analyzed using ATLAS.ti to extract and compare causality-related language across drug labeling sections.

Results

Our analysis identified heterogeneous and sometimes contradictory causality assessment evidentiary thresholds across US drug label sections. We found no predefined or standardized causality thresholds specified in FDA regulations, allowing interpretive flexibility that may contribute to variability and opacity in labeling decisions. For example, the Adverse Reactions section requires “some basis to believe” a causal relationship, while the Warnings and Precautions section states that “reasonable evidence” of causality is needed for serious events.

Conclusion

We recommend greater standardization of causality-related terminology and public documentation of evidentiary rationales supporting labeling decisions. Improved clarity regarding evidence certainty would better support prescribers and patients in understanding drug-related harms and strengthen public trust in regulatory drug safety assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug LabelingDrug-Related Side Effects and Adverse ReactionsUnited StatesHumansCausality

Autor:innen und Institutionen

  • Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA. saraht24@stanford.edu.
  • Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA. saraht24@stanford.edu.
  • Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
  • Medical Safety for Marketed Products Development, Plasma-Derived Therapies, Medical Devices, and Vaccines, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
  • Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA.
  • Departments of Medicine and of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.

Zitieren

APA

Tanveer, S., Castillo, W. C., Wastila, L., Hammad, T. A., Cooke, C. E., Ioannidis, J. P. A., & Doshi, P. (2026). Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents. Drug Safety, 49(12), 1649-1656. https://doi.org/10.1007/s40264-026-01710-5

Vancouver

Tanveer S, Castillo WC, Wastila L, Hammad TA, Cooke CE, Ioannidis JPA, et al. Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents. Drug Safety. 2026;49(12):1649-1656. doi:10.1007/s40264-026-01710-5

BibTeX
@article{Tanveer2026,
  author = {Tanveer, Sarah and Castillo, Wendy Camelo and Wastila, Linda and Hammad, Tarek A and Cooke, Catherine E and Ioannidis, John P A and Doshi, Peter},
  title = {Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents},
  journal = {Drug Safety},
  year = {2026},
  volume = {49},
  number = {12},
  pages = {1649--1656},
  doi = {10.1007/s40264-026-01710-5}
}
Kostenlos starten →